Showing 1631-1640 of 3038 results for "".
- EyeQue Expands Vision Monitoring for Consumers, Adding Color and Contrast Sensitivity Tests to Insight Vision Screenerhttps://modernod.com/news/eyeque-expands-vision-monitoring-for-consumers-adding-color-and-contrast-sensitivity-tests-to-insight-vision-screener/2479923/EyeQue announced the addition of two new vision tests to its EyeQue Insight vision screener—color vision and contrast sensitivity testing. The EyeQue Insight combines a binocular viewer, mobile application and cloud-based service to create the world’s first smartphone-powered vision screener, acc
- Oculocare’s Alleye Receives FDA 510(k) Clearance for Monitoring Eyesight in AMDhttps://modernod.com/news/oculocares-alleye-receives-fda-510k-clearance-for-monitoring-eyesight-in-amd/2480036/Oculocare Medical announced the FDA 510(k) clearance of Alleye, a mobile medical software application indicated for the detection and monitoring of age-related macular degeneration (AMD). Alleye is designed to detect and characterize central and paracentral metamorphopsia (visual distortio
- Versea Ophthalmics Announces Novel Application of Biovance Product Portfolio in Retinal Procedureshttps://modernod.com/news/versea-ophthalmics-announces-novel-application-of-biovance-product-portfolio-in-retinal-procedures/2482787/Verséa Ophthalmics has announced that results from recent application of Biovance and Biovance 3L Ocular products in macular hole repair will be presented at the upcoming Retinal World Congress (RWC) being held from May 8-11, 2025 in Fort Lauderdale, FL. The macula
- PulseSight Therapeutics Launches to Advance Non-Viral Gene Therapies for Severe Retinal Diseaseshttps://modernod.com/news/pulsesight-therapeutics-launches-to-advance-non-viral-gene-therapies-for-severe-retinal-diseases/2482134/PulseSight Therapeutics launched today with a portfolio that includes two first-in-class late-stage preclinical drugs for wet and dry age-related macular diseases (AMD), including geographic atrophy (GA). PulseSight’s proprietary non-viral gene therapy ocu
- BVI Expands its Presence in Spain and Portugal Acquiring Medical Mixhttps://modernod.com/news/bvi-expands-its-presence-in-spain-and-portugal-acquiring-medical-mix/2481813/BVI announced it has acquired Medical Mix, an ophthalmic medical device supplier in Spain and Portugal. Financial terms of the deal were not disclosed. BVI said its European footprint with direct sales representatives and infrastructure now spans all major western Eu
- Norlase Receives FDA 510(k) Clearance and CE Mark Approval For ECHO Green Pattern Laserhttps://modernod.com/news/norlase-receives-fda-510k-clearance-and-ce-mark-approval-for-echo-green-pattern-laser/2481597/Norlase has received both FDA 510(k) clearance and CE Mark approval for the ECHO Green Pattern Laser photocoagulator. ECHO is a portable scanning laser photocoagulator utilizing MEMS technology. The laser and scanner are completely integrated into a single delivery device that
- Registration Now Open for Neuro-Optometric Rehabiliation Association 2023 Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabiliation-association-2023-conference/2481568/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) 33rd annual conference, October 5-8, at the Portland Marriot Downtown Waterfront in Portland, Oregon. The NORA annual conference is an event for eye care and other health care
- BVI Announces Certification for its IOL Portfolio Under the European Medical Device Regulationhttps://modernod.com/news/bvi-announces-certification-for-its-iol-portfolio-under-the-european-medical-device-regulation/2481094/BVI announced certification for its IOL portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹. The new regulatory criteria came into effect in May 2021, replacing the prior Medica
- Alimera Announces Reimbursement of Uveitis Indication Granted for Iluvien in Portugalhttps://modernod.com/news/alimera-announces-reimbursement-of-uveitis-indication-granted-for-iluvien-in-portugal/2481021/Alimera Sciences announced that Alimera Sciences Europe, its Ireland-based European subsidiary, has been granted reimbursement in Portugal for Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for noninfectious uveitis affecting the pos
- Euclid Vision Announces Official Launch of Cloud-Based Portalhttps://modernod.com/news/euclid-vision-announces-official-launch-of-cloud-based-portal/2480964/Euclid Vision has announced the official rollout of MyEuclid, an interactive, web-based customer portal designed to drive practice efficiency and optimize Euclid Ortho-K fits. The MyEuclid portal was released on a limited basis earlier this year, and the platform is now availa